A familial Alzheimer's genetic panel is a blood test that sequences the three genes known to cause inherited, early-onset Alzheimer's disease — APP, PSEN1, and PSEN2. For most adults with new memory symptoms, a referral to genetic counseling and testing makes sense only when there's a specific family pattern behind those symptoms: a parent, sibling, or multiple relatives diagnosed with dementia well before age 65. The test itself is straightforward to order once a clinician identifies that pattern, but what it costs and whether insurance pays for it depends heavily on family history, symptom onset, and which lab runs it. The sections below walk through who typically qualifies, what the panel costs out of pocket, how insurers decide coverage, and a related but separate test — APOE genotyping — that has become newly relevant for people being considered for anti-amyloid drug treatment.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who Actually Needs This Panel?
- What Does the Test Cost?
- When Will Insurance Cover It?
- Is APOE Testing the Same Thing?
- What If the Referral Is Hard to Get?
- What a Result Does and Doesn't Tell You
- Frequently Asked Questions
Who Actually Needs This Panel?
A familial Alzheimer's panel isn't a routine add-on for ordinary memory complaints. The 2011 ACMG/NSGC joint practice guideline states that genetic testing for Alzheimer's should happen only within the context of genetic counseling, and it's most useful when there's an autosomal-dominant family history — meaning dementia has appeared in multiple generations, with at least one relative diagnosed at an unusually young age. That family pattern is the clinical signal that separates typical late-life memory loss from a heritable mutation.
A single relative with Alzheimer's in their 80s doesn't point toward APP, PSEN1, or PSEN2. A parent or sibling diagnosed in their 40s or 50s, especially alongside other affected relatives across generations, is the scenario this test was built for. Because the guideline requires counseling before and after testing, the practical first step for a reader with new memory symptoms and this kind of family history is asking a primary care doctor or neurologist for a referral to a genetic counselor, not requesting the panel directly from a lab.
What Does the Test Cost?
Pricing varies depending on whether you're looking at a lab's published rate or what a patient actually pays after insurance. PreventionGenetics lists its APP/PSEN1/PSEN2 familial Alzheimer's panel at a $990 list price, with a 25% surcharge if rush processing is needed — but that figure is the lab's list price, not necessarily what shows up on a patient's bill. Actual out-of-pocket cost tends to be lower.
A 2025 UW Health genetic-counseling presentation reports that patients typically pay somewhere between $0 and $1,000 for these panels across several clinical labs, with $300 being a common amount. Turnaround runs about three weeks. That range reflects how much insurance coverage, lab billing practices, and financial assistance programs can shift the final cost. Asking the ordering clinic which lab they use, and whether that lab offers a patient-pay or sliding-scale rate, is a reasonable question before testing begins.
When Will Insurance Cover It?
Coverage decisions follow fairly specific eligibility rules, and they differ somewhat by insurer. Blue Cross NC's medical policy covers PSEN1/PSEN2/APP testing for people with a family history of autosomal-dominant dementia — defined as one or more cases of dementia before age 65 — as well as for someone with a first-degree relative who already has a known causative mutation, or for a symptomatic person with early-onset disease and no known family history, such as an adoptee who can't trace relatives. Medica's policy draws the line a bit differently.
For adults 18 and older, Medica's coverage criteria require an asymptomatic person to have a first- or second-degree relative who already carries a known mutation. A symptomatic person qualifies if dementia began at or before age 65, combined with either an affected relative or a family history that simply isn't known. In both policies, the common thread is early onset plus a documented or plausible genetic family pattern. A person with typical late-onset memory symptoms and no early-onset relatives is unlikely to meet either insurer's criteria, which is part of why the referral question matters as much as the cost question.
Is APOE Testing the Same Thing?
No — APOE genotyping is a different test with a different purpose, and it's commonly confused with the APP/PSEN1/PSEN2 panel. Blue Cross NC classifies standalone APOE genotyping as investigational for general Alzheimer's risk assessment, meaning routine diagnostic APOE testing to gauge someone's risk is typically not a covered benefit outside of a specific treatment-related use. That treatment-related use has become significant.
The current FDA label for lecanemab (Leqembi) states that ApoE ε4 genotype testing should be performed before starting treatment, because people who carry two copies of the ε4 variant — about 15% of Alzheimer's patients — face a higher rate of ARIA, a drug-related brain swelling or bleeding side effect, including severe cases, compared with people who carry one copy or none. The scale of that difference is substantial. In the Clarity AD trial data behind the FDA label, ARIA occurred in 40% of ApoE ε4 homozygotes taking lecanemab versus 21% on placebo, compared with 11% of non-carriers on the drug versus 4% on placebo. So for a reader whose memory symptoms are prompting a conversation about anti-amyloid treatment rather than a family-history-driven diagnostic workup, APOE testing — not the familial panel — is the relevant test, and it's ordered for a different reason entirely.
What If the Referral Is Hard to Get?
Demand for APOE counseling has outpaced the number of genetic counselors available to provide it. A 2025 conference abstract notes that the volume created by anti-amyloid therapy made it infeasible for genetic counselors to see every patient with mild cognitive impairment or early Alzheimer's who needed APOE counseling, prompting the NSGC Dementia Workgroup to begin formally updating the 2011 joint guideline.
That bottleneck is worth knowing about before assuming a long wait means something has gone wrong. If a referral for APOE testing ahead of a treatment decision is moving slowly, it may reflect counselor capacity rather than a problem with the request itself — a reasonable thing to ask the referring clinic about directly. For the APP/PSEN1/PSEN2 diagnostic panel specifically, the same counseling requirement applies, so a reader whose family history clearly meets the criteria above should expect the referral to go through genetic counseling rather than coming straight from a neurologist's office.
What a Result Does and Doesn't Tell You
A positive result on the familial panel is informative, but a negative one isn't the end of the story. ARUP Laboratories' early-onset Alzheimer's sequencing panel identifies a causative variant in roughly 60–80% of familial early-onset cases — meaning a meaningful share of families with a clear inherited pattern still won't get a positive hit.
That gap exists because the panel sequences coding regions and the boundaries between introns and exons, not every possible genetic change that could affect these genes. A negative result in a family with strong autosomal-dominant history doesn't rule out a heritable form of the disease; it means the specific mutation types this panel can detect weren't found. That distinction is worth discussing with the genetic counselor delivering the result, since it shapes what, if anything, comes next for other family members.
Frequently Asked Questions
Does a negative genetic panel mean Alzheimer's isn't inherited in my family?
Not necessarily. ARUP Laboratories' panel finds a causative mutation in about 60–80% of familial early-onset cases, so a negative result can miss mutations outside the regions it sequences.
Why would someone need APOE testing instead of the APP/PSEN1/PSEN2 panel?
APOE testing serves a different purpose — the FDA label for lecanemab requires it before starting treatment to assess ARIA risk, while the APP/PSEN1/PSEN2 panel diagnoses inherited early-onset Alzheimer's.
Can I order this testing without seeing a genetic counselor?
The ACMG/NSGC guideline specifies that testing should occur within genetic counseling, both before and after the test, so most referral pathways route through a counselor rather than direct lab ordering.
